Skip to content
Dx

ICD-10-CM 2027 diagnosis code

R76.89Other specified abnormal immunological findings in serum

✓ Billable / specific

R76.89 is a valid, billable ICD-10-CM code for other specified abnormal immunological findings in serum. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Code last changed in FY2026 (effective October 1, 2025). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About R76.89

R76.89 is the ICD-10-CM diagnosis code for other specified abnormal immunological findings in serum. It belongs to category R76 (other abnormal immunological findings in serum), block R70-R79 (abnormal findings on examination of blood, without diagnosis) and chapter 18 (symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within R76.8, choose R76.89 (Other specified abnormal immunological findings in serum) only when documentation doesn't support a more specific option: abnormal rheumatoid factor and anti-citrullinated protein antibody without rheumatoid arthritis (R76.81).

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 814 (Reticuloendothelial and Immunity Disorders with MCC, relative weight 2.0729), DRG 815 (Reticuloendothelial and Immunity Disorders with CC, relative weight 1.0444) and DRG 816 (Reticuloendothelial and Immunity Disorders without CC/MCC, relative weight 0.7381), in MDC 16 (Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It was added in FY2026, effective October 1, 2025.

Coding notes

Applicable toConditions and synonyms classified to this code
  • Raised level of immunoglobulins NOS

Notes that apply from higher levels

Instructions written at a parent level also apply to R76.89.

Broader instructions also apply from R70-R79 Abnormal findings on examination of blood, without diagnosis and Chapter 18: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified.

Alphabetic index entries

3 entries

Terms in the official ICD-10-CM index that lead to R76.89.

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2026 (effective 10/1/2025): Added
  • No changes since FY2026.

Common questions about R76.89

Is R76.89 billable?

Yes. R76.89 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can R76.89 be used as a principal diagnosis?

Yes. The Medicare Code Editor doesn't restrict R76.89 as a principal diagnosis.

Is R76.89 a CC or MCC?

No. R76.89 is neither a CC nor an MCC under MS-DRG v44.0.

What DRG does R76.89 group to?

R76.89 is used in the MS-DRG v44.0 logic for MS-DRG 814 (Reticuloendothelial and Immunity Disorders with MCC), MS-DRG 815 (Reticuloendothelial and Immunity Disorders with CC) and MS-DRG 816 (Reticuloendothelial and Immunity Disorders without CC/MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.